Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 2/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15021624 | 0.91 | PDPK1 (0.48) | ULK1LRRK2PDPK1 | |
| SCHEMBL13854959 | 0.82 | ULK1 (0.62) | ULK1MAPK1PDPK1 | |
| SCHEMBL173292 | 0.77 | ULK1 (0.74) | ULK1LRRK2MAPK1PDPK1MAPK3 | |
| SCHEMBL8251891 | 0.76 | ULK1 (0.61) | ULK1MAPK1PDPK1 | |
| SCHEMBL168798 | 0.74 | LRRK2 (0.50) | ULK1LRRK2MAPK1MAPK3MAP2K2 | |
| SCHEMBL15046120 | 0.74 | LRRK2 (0.50) | ULK1LRRK2MAPK1PDPK1MAPK3 | |
| SCHEMBL5377558 | 0.72 | LRRK2 (0.62) | LRRK2PDPK1 | |
| SCHEMBL5378622 | 0.70 | TTK (0.56) | MAPK1MAPK6 | |
| SCHEMBL15021783 | 0.70 | MAPK1 (0.46) | ULK1LRRK2MAPK1PDPK1MAPK3 | |
| SCHEMBL9986485 | 0.70 | AKT1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2613782-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | claimed |
| EP-2613782-A2 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-17 | — | — | EP | claimed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | claimed |
| WO-2012030685-A2 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-08 | — | — | WO | claimed |
| EP-2613782-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2613782-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8946216-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946216-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MAPK3, MAPK1, MAP3K1 | ULK1 303/4885LRRK2 339/4885MAPK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.